Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase.
Wei ShiGuang XuYuan GaoJun ZhaoTingting LiuJia ZhaoHuijie YangZiying WeiHui LiAn-Long XuZhaofang BaiXiaohe XiaoPublished in: Journal of translational medicine (2023)
Our study indicated that epalrestat, an aldose reductase inhibitor, effectively suppressed NLRP3 inflammasome activation in vivo and in vitro and might be a new therapeutic approach for NASH.
Keyphrases